Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Climb On Equipment
San Francisco, CA, USAclimb.bio ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Climb Bio is a clinical-stage biotechnology company dedicated to developing precision therapies for rare childhood-onset epilepsies. The company utilizes a proprietary zebrafish-based phenotypic screening platform to identify small molecules that modulate serotonin signaling to reduce seizure activity. Its lead candidate, EPX-100 (clemizole hydrochloride), is currently in Phase 2 clinical trials for the treatment of Dravet syndrome. By repurposing and optimizing existing compounds, Climb Bio aims to provide safer and more effective treatment options for patients with severe, treatment-resistant seizure disorders.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Climb On Equipment.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Climb On Equipment.